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Circulating insulin-like growth factor I
modulates mood and is a biomarker of
vulnerability to stress: from mouse to man
A. Santi1,2, M. Bot3, A. Aleman4, B. W. J. H. Penninx3 and I. Torres Aleman 1,2
Abstract
Individual susceptibility to anxiety disorders after maladaptive responses to stress is not well understood. We now
report that while exploring stress responses in mice after traumatic brain injury (TBI), a condition associated to stress
susceptibility, we observed that the anxiogenic effects of either TBI or exposure to life-threatening experiences
(predator) were blocked when both stressors were combined. Because TBI increases the entrance into the brain of
serum insulin-like growth factor I (IGF-I), a known modulator of anxiety with a wide range of concentrations in the
human population, we then determined whether circulating IGF-I is related to anxiety measures. In mice, anxiety-like
responses to predator were inversely related to circulating IGF-I levels. Other indicators of mood regulation such as
sensitivity to dexamethasone suppression and expression levels of blood and brain FK506 binding protein 5 (FKBP5), a
co-chaperone of the glucocorticoid receptor that regulates its activity, were also associated to circulating IGF-I. Indeed,
brain FKBP5 expression in mice was stimulated by IGF-I. In addition, we observed in a large human cohort (n= 2686) a
signiﬁcant relationship between plasma IGF-I and exposure to recent stressful life events, while FKBP5 expression in
blood cells was signiﬁcantly associated to plasma IGF-I levels. Collectively, these data indicate that circulating IGF-I
appears to be involved in mood homeostasis across different species. Furthermore, the data in mice allow us to
indicate that IGF-I may be acting at least in part by modulating FKBP5 expression.
Introduction
Affective disorders affect many people worldwide and
currently represent an increasing health burden1. Dysre-
gulation of stress homeostasis is considered a key step in
development of these disorders, and is a characteristic of
conditions such as post-traumatic stress disorder (PTSD)
and associated anxiety disorders2. PTSD is a heritable
condition, and although genetic risk factors are slowly
being unveiled3, vulnerability to PTSD, and to maladap-
tive stress responses in general, is not yet fully under-
stood. Indeed, responses to stress show a wide individual
variation4. For instance, only a subset of combatants
develops PTSD after exposure to similar war conditions5.
One factor proposed to contribute to development of
PTSD in war ﬁghters/car accident survivors is traumatic
brain injury (TBI)5–7. However, because there are also
reports that TBI may protect against PTSD, it has been
hypothesized that when damage encompasses brain areas
putatively involved in stress responses such as prefrontal
cortex and amygdala, PTSD does not develop6,8. The
latter observation opens the possibility to explore endo-
genous mechanisms of protection against PTSD related to
TBI, and probably of vulnerability to stress in general.
Among many potential candidates of endogenous pro-
tective mechanisms we focused on two: insulin-like
growth factor I (IGF-I) and FK506 binding protein 5
(FKBP5). The former is an abundant circulating hormone
mostly produced by the liver9. Blood IGF-I levels in the
normal population show a wide range of values, with
individuals in the lower or higher ends showing greater
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susceptibility to different diseases10–15. Some, but not all
studies, show that IGF-I is increased in affective dis-
orders16,17. In addition, IGF-I has been documented as a
mood regulator18,19, as for example through its potent
anxiolytic actions20. Furthermore, we recently observed
that TBI induces the entrance of serum IGF-I into the
brain21. Thus, IGF-I may be involved in mood regulation
after TBI.
In turn, FKBP5 is an Hsp90-associated co-chaperone
that regulates the responsiveness of steroid hormone
receptors, including glucocorticoids, major regulators of
mood and PTSD responses22. FKBP5 has been proposed
Fig. 1 A role for circulating IGF-I in anxiety. a Submitting mice to either TBI or exposure to a predator (stressed mice) signiﬁcantly increased
anxiety levels as measured 1 week after in the elevated plus maze (EPM) as time spent in the open arms. However, when both stressors are
combined, anxiety is not increased over basal levels (interaction between stress and injury F(1,111)= 20.174, p < 0.0001; n= 38, 10, 32, 35 respectively).
b Intracerebroventricular administration of IGF-I to intact mice attenuates anxiety responses to predator exposure as determined in the EPM (t=
3.606, df= 13, n= 7 and 8). c Similarly reduced anxiety was seen when placing the mice in an open ﬁeld, as IGF-I-treated mice showed greater time
in the center of the arena (t= 2.242, df= 13, n= 7 and 8). d Combined action of TBI and a life-threatening event (predator exposure) on anxiety
levels in mice with low serum IGF-I (LID mice). These mice showed greater basal anxiety as compared to control mice (see panel a), enhanced anxiety
after TBI injury, and even greater anxiety when TBI was combined to predator exposure (no signiﬁcant interaction; effects of injury F(1,46)= 15.15; p=
0.0003 and stress F(1,46)= 4.71; p= 0.0352; n= 12, 11, 13, 14, respectively). e Treatment of LID mice with systemic IGF-I ameliorated anxiety after
combined TBI and rat exposure (Mann−Whitney p= 0.0012; n= 7 in both groups). *p < 0.05; **p < 0.01, and ***p < 0.001 vs. respective controls in
this and following ﬁgures
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to mediate environmental and genetic interactions in
mood regulation23, and is associated to stress resilience,
PTSD risk, and affective disorders24–26. Thus, FKBP5 may
also be involved in modulation of stress responses after
TBI.
Based on the above observations we consider likely that
circulating IGF-I may modulate mood and speculate that
FKBP5 may be involved in the actions of IGF-I. Thus, in
the present work, we analyzed anxiety-like responses to
TBI and/or predator exposure, and FKBP5 expression in
mice with varying levels of serum IGF-I. We also per-
formed a cross-sectional study in humans categorized
according to serum IGF-I levels to analyze a possible
relationship between serum IGF-I and measures of stress
exposure and FKBP5 expression. We found that serum
IGF-I levels impact on anxiety responses and modulates
brain expression of FKBP5 in mice, whereas in humans,
lower levels of circulating IGF-I signiﬁcantly correlated
with higher occurrence of stressful events and lower
FKBP5 expression.
Results
Exploring a link between life-threatening events and brain
trauma in anxiety-like behavior in mice
Exposure of naïve mice to life-threatening events such
as a rat, a natural predator that elicits a marked increase in
serum levels of the stress hormone corticosterone (Suppl
Figure A), increased their anxiety levels, as shown by a
decrease in the time spent in the open arms of the ele-
vated plus maze (Fig. 1a). Similarly, physical stress pro-
duced by a TBI also enhanced anxiety in wild-type mice
(Fig. 1a). However, when both stressors (predator expo-
sure+TBI) are combined, as is often the case for PTSD-
triggering scenarios6,7, the time spent in the open arms of
the elevated plus maze (as a measure of anxiety-like
behavior) was not different from nonstressed, nonlesioned
intact mice (Fig. 1a). Differences in time spent in open
arms were not related to differences in exploratory activity
of the experimental groups as all of them showed similar
number of entries in the arms (Supp Figure B).
Next, we determined whether TBI-induced entrance of
serum IGF-I into the brain21 could ameliorate stress
responses after combined TBI and predator exposure, as
IGF-I modulates mood20. First, we administered intra-
cerebroventricular IGF-I to intact mice to mimic the
increase in IGF-I produced by TBI21, and 2 days later we
submitted them to predator stress. We observed that
treatment with IGF-I, but not its vehicle, signiﬁcantly
attenuated the stress response to predator exposure, as
determined both by reduced anxiety in the elevated plus
maze (Fig. 1b) and in the open ﬁeld (Fig. 1c). To conﬁrm a
role of IGF-I in anxiolysis, we then determined anxiety
levels after combined exposure to TBI and predator in
mutant mice with low serum IGF-I levels (LID mice), that
show only a modest increase in brain IGF-I levels after
TBI21. We observed that LID mice displayed an enhanced
increase in anxiety after exposure to predator and TBI
(Fig. 1d). This is in marked contrast with wild-type mice
exposed both to TBI+ predator, that did not show
changes in anxiety (Fig. 1a, right-most bar). As normal-
ization of brain function in LID mice is possible by
treating them with systemic IGF-I27, we analyzed if their
Fig. 2 Low serum IGF-I alters corticosterone responses to stress. a LID animals show signiﬁcantly greater basal levels of corticosterone in blood
(p < 0.001, white bars), as well as a prolonged suppression of this hormone 2 days after exposure to TBI (solid bars, signiﬁcant interaction between
injury and genotype F(1, 15)= 41.17; p < 0.001; n= 8 and 9, in WT and LID respectively). b, c Suppression of corticosterone by dexamethasone is
delayed in LID mice, being stronger at 3 h after dexamethasone treatment (c) than 2 h after injection (b). Signiﬁcant effect of treatment (F(1, 28)=
5.466; p= 0.0268) and genotype (F(1, 28)= 23.10; p < 0.0001) 2 h after DEX administration (b), and signiﬁcant interaction between genotype and
treatment (F(1, 28)= 5.300; p= 0.0290) 3 h after the injection (n= 8 in each group)
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exaggerated anxiety response could be attenuated after
systemic IGF-I treatment. Indeed, IGF-I administration to
LID mice exerted an anxiolytic effect, as reﬂected by a
signiﬁcantly greater time spent in the open arms of the
EPM (Fig. 1e).
Serum IGF-I and the HPA axis
The above data pointed to a link between serum IGF-I
and anxiety. Accordingly, we observed that LID mice that
showed increased anxiety in the elevated plus maze (Fig.
1) had an altered HPA axis. Mice with low serum IGF-I
had higher basal serum corticosterone levels (Fig. 2a, bars
of basal values), together with higher sensitivity of the
HPA axis, as indicated by protracted reduction of serum
corticosterone after dexamethasone suppression (Fig. 2b,
c). Based on the latter, we examined whether LID mice
had also abnormally delayed corticosterone reduction
after exposure to the physical stress produced by TBI, that
increases corticosterone28, and found that corticosterone
levels remained low 2 days after injury (Fig. 2a).
To start exploring mechanisms connecting IGF-I with
the regulation of the HPA axis we determined the levels of
the co-chaperone FKBP5, an important determinant of
the activity of the glucocorticoid receptor that is related to
PTSD risk24 and stress-sensitive brain systems29. We
found that low serum IGF-I in LID mice parallels lower
levels of expression of FKBP5 in blood, hypothalamus, and
hippocampus (Fig. 3a−c). Furthermore, IGF-I stimulated
expression of FKBP5 in mixed hypothalamic cultures (Fig.
3d). Since serum IGF-I likely impacts on the activity of the
HPA axis by modulating FKBP5, it may help assess the
activity of this neuroendocrine axis. Indeed, in control
mice, serum IGF-I levels correlated with anxiety levels, as
measured in the elevated plus maze (Fig. 4a).
Based on these observations in mice, and because of its
potential clinical utility as a biomarker of vulnerability to
stress, we determined in a large human cohort (Nether-
lands Study of Depression and Anxiety, NESDA) whether
plasma IGF-I levels were related with measures of stress
exposure, HPA activity, and FKBP5. Data were available
for up to 2686 NESDA participants (mean age 41.7 (SD
13.0) years, and 66% females). Table 1 shows the asso-
ciations of IGF-I with number of life events in the past
year, childhood trauma, dexamethasone suppression ratio,
and FKBP5 expression. We found a positive association
between the lowest quintile of IGF-I (compared to the
middle quintile) and number of life events, suggesting that
persons that were in the lowest quintile of IGF-I had
experienced 1.17 times more life events than persons in
the middle quintile. IGF-I was not related to any of the
other stress measures. Furthermore, IGF-I as a con-
tinuous measure was positively associated with averaged
FKBP5 expression.
Discussion
The present observations support the hypothesis that
circulating IGF-I modulates mood at least in part by
modulating FKBP5 activity. While prior observations
suggested that IGF-I might be involved in affective dis-
orders (see introduction), these results reveal a speciﬁc
role for circulating IGF-I in mood homeostasis, as gath-
ered from experimental data in mice and epidemiological
data from a large human cohort. Since circulating IGF-I is
mostly produced by the liver9, this suggests that this
peripheral organ is involved in mood regulation. Indeed,
glucocorticoids, major modulators of mood30, are well-
known regulators of serum IGF-I levels31–33, which in
turn also modulate glucocorticoid production34.
Fig. 3 FKBP5 is regulated by IGF-I. a LID mice with low serum IGF-I
have lower levels of FKBP5 mRNA in blood (t= 2.82; df= 9; p= 0.02;
n= 5 and 6, respectively); b in hypothalamus (t= 8.503; df= 21; p <
0.0001; n= 14 and 9, respectively); c and in hippocampus (t= 2.7; df
= 12; p= 0.0193; n= 5/9, respectively). d Treatment of mixed
hypothalamic cultures with IGF-I increases expression of FKBP5 (t=
2.587; df= 8; p= 0.0323; n= 5 for both groups)
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We have seen that in mice, serum IGF-I is an important
determinant of anxiety-like responses. Assessment of
underlying mechanisms indicated that circulating IGF-I
impacts on the activity of the HPA axis, probably in part
by regulating FKBP5 expression, which is also regulated
by glucocorticoids35, and in this way regulates anxiety.
Analysis of this relationship in the NESDA human cohort
showed that persons with greater vulnerability to stress, as
Fig. 4 IGF-I and anxiety. a A signiﬁcant correlation was seen between serum IGF-I levels and anxiety measured in the EPM (F (1,18)= 6.483; p=
0.0203; n= 20). b Proposed mechanisms mediating serum IGF-I effects on mood. Circulating IGF-I potentiates hippocampal neurogenesis and
neurotrophic signaling, as already published27,39, while it also stimulates FKBP5 in brain, modulating in this way the activity of the brain glucocorticoid
receptor that eventually impacts on mood homeostasis
Table 1 Association of IGF-I with clinical and gene expression variables in a large-scale human sample
Outcomes





n= 2686 n= 2676 n= 1706 n= 1811
Poisson regression Logistic regression Linear regression Linear regression






1.00 (0.99−1.02), 0.58 0.000 (−0.001 to 0.002), 0.56 0.003 (0.000−0.005),
0.03
2. IGF-I quintiles
Q1 1.17 (1.03–1.32), 0.02 0.94 (0.73–1.20), 0.59 −0.019 (−0.053 to 0.015), 0.27 −0.033 (−0.085 to 0.018),
0.20
Q2 0.99 (0.87–1.12), 0.83 0.88 (0.69–1.13), 0.31 −0.006 (−0.039 to 0.028), 0.75 0.044 (−0.006 to 0.094),
0.08
Q3 (reference)
Q4 0.98 (0.86–1.12), 0.79 0.80 (0.62–1.02), 0.07 0.002 (−0.032 to 0.035), 0.92 −0.002 (−0.054 to 0.049),
0.93
Q5 1.00 (0.88–1.14), 0.99 1.11 (0.87–1.42), 0.40 −0.006 (−0.039 to 0.028), 0.74 0.036 (−0.015 0.087), 0.17
Bold values indicate signiﬁcant differences
All analysis are adjusted for: sex, age, age2, education level, smoking, BMI, physical activity, glucose
CI conﬁdence interval, IGF-I insulin-like growth factor I, OR odds ratio, RR rate ratio
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determined by reported stressful occurrences but not by
other measures of stress vulnerability, had the lowest
levels of serum IGF-I. In turn, IGF-I also correlated with
FKBP5 levels in this human cohort. Previously, the
NESDA study showed positive association between IGF-I
and depressive and anxiety disorders when controlling for
antidepressant medication use17.
Although limitations of NESDA need to be accounted
for, including that persons with a depressive and/or
anxiety disorder were overrepresented, no measures of
PTSD were done in the baseline study and other, maybe
more relevant stress vulnerability measures were not
included, we consider that these data, in conjunction with
the results in mice allow us to suggest that measurement
of serum IGF-I may help in the clinical assessment of
susceptibility to stress. While more studies are needed,
these results could help explain individual vulnerability to
stress situations after TBI, with patients with lower IGF-I
levels being at greater risk. This is an important point,
since the relationship between TBI and PTSD risk is not
entirely clear6. Because IGF-I directly modulates FKBP5
in brain cells, and serum IGF-I can enter into the brain in
a regulated fashion36, the reported anxiolytic actions of
pharmacological boosting of IGF-I37 can be explained by
the present observations. Indeed, we provide direct evi-
dence of anxiolysis by IGF-I in mice. Ultimately, these
observations could help to clarify the relationship between
TBI and PTSD, as subjects with lower serum IGF-I/
FKBP5 will likely show greater susceptibility to PTSD.
In this regard, our work in experimental models allow
us to hypothesize that TBI-induced uptake of serum IGF-I
by the brain will be reduced in individuals with low serum
IGF-I, as seen previously in mice21. Reduced entrance of
IGF-I will impact on brain glucocorticoid receptor sen-
sitivity, that is altered after TBI38, at least in part through
regulation of brain FKBP5 expression, as evidenced by
exacerbated stress responses in mice with low serum IGF-
I (LID mice). A role for IGF-I is corroborated by our
observation that intracerebroventricular administration of
this growth factor in control mice greatly attenuates
subsequent stress responses. Other potential anxiolytic
actions of IGF-I, including promotion of hippocampal
neurogenesis and growth factor responses39,40, will be also
reduced if insufﬁcient IGF-I is available. In mice with low
serum IGF-I, the observed prolonged corticosterone
reduction after TBI will likely interfere with the sub-
sequent stress response to predator exposure, leading to
exacerbated anxiety. In humans, as no correlation of cir-
culating IGF-I with dexamethasone suppression was
observed, other mechanisms downstream of low IGF-I
may be involved.
The association between serum IGF-I and measures of
mood regulation (anxiety, etc) might be bi-directional.
That is, serum IGF-I and mood may inﬂuence each other.
In this regard, it is well-known that glucocorticoids, that
are altered in mood disorders, and IGF-I inﬂuence each
other31,34,. Based on the observations in LID mice,
reduced serum IGF-I (as a result of genetic ablation of the
liver IGF-I gene) is associated to enhanced anxiety and
diminished capacity to cope with stress. In turn, early
stressful events may lead to lower serum IGF-I levels in
humans, as was recently reported in infant rats41. Indeed,
lower socioeconomic status correlates with lower serum
IGF-I42, probably in part due to poorer nutrition43, but
probably also because of increased exposure to stress
conditions associated to low income44. Intriguingly, lower
serum IGF-I levels have been shown to be associated to
lower social rank/sociability across the phylogenetic
tree45–48. Furthermore, prolonged lower serum IGF-I
leads to depressive states in mice19. Conversely, it has
been observed that enhanced resilience to stress in adult
mice reared under enriched environment is mediated by
serum IGF-I18. However, serum IGF-I levels are higher in
affective disorders in humans16,17, which may indicate an
adaptive/resistant process, but this remains to be
explored. At any rate, our observations ﬁt well with a
previously noted role of serum IGF-I in mood
homeostasis.
In summary, we now provide evidence that the asso-
ciation of TBI with subsequent anxiety-like behaviors may
depend on serum IGF-I levels prior to insult. Serum IGF-I
levels are likely to inﬂuence the impact of TBI on mood
homeostasis because brain IGF-I levels after TBI increase
in proportion to circulating IGF-I levels21. Of broader
consequence, IGF-I levels may contribute, together with
other relevant variables, to a “risk proﬁle” of vulnerability
to stress in populations at risk, or even in the general
population, with low levels positing as a risk factor to
stress vulnerability. At any rate, larger studies in humans
are needed to establish whether blood IGF-I levels may
serve as a biomarker of stress vulnerability. Of note, as
serum IGF-I levels can be increased by pharmacological,
behavioral, and nutritional intervention37,43,49, vulner-




Adult male control (C56BL/6JolaHsd; 28–35 g) and
mutant mice with low serum IGF-I (LID mice; 27–38 g),
and adult male and female Wistar rats (200–450 g)
obtained from the Cajal Institute were used. Mice were
housed in standard cages (48 × 26 cm2; 5 per cage), while
rats were housed in standard cages with 1–2 rats per cage.
All animals were kept on a light−dark cycle (12–12 h) in a
room with constant temperature (22 °C) and humidity,
and with food (pellet rodent diet) and water ad libitum.
All experimental protocols were performed during the
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light cycle. Mice were handled for 3 days prior to any
experimental manipulations. Animal procedures followed
European guidelines (86/609/EEC, European Council
Directives) and were approved by the local Bioethics
Committee.
Controlled cortical injury (CCI)
Time-line and experimental design are shown in Suppl
Figure G. An electromagnetic stereotaxic impactor
(Impact OneTM, MyNeuroLab, Leica, Germany) was used
to induce a mild CCI injury, as previously described in
detail elsewhere21. Sham injured animals were submitted
to the same procedure except for the impact.
Behavioral tests
Predator exposure
C57BL/6 and LID animals were exposed to a rat for
10min. Mice were assigned to the control or stressed
group in a randomized way. A box containing the rat was
divided by a plastic mesh leaving the rat in one of the two
compartments. Mice were introduced in the other com-
partment protected by the mesh. This allowed them to
see, smell and touch the rat without being harmed. The
ﬂoor bedding had urine and feces from the rat. Every
experimental day each rat was used to stress a maximum
of three mice. Control animals were exposed to a similar
box with clean bedding and in the opposite compartment,
instead of a rat, there was a toy rat.
Open ﬁeld
Mice were introduced in a 42 cm × 42 cm × 30 cm arena
(Versamax; AccuScan Instruments, Inc.) for 5 min. Time
exploring the center of the open ﬁeld and total distance
was quantiﬁed automatically with the software provided
by the manufacturer.
Elevated plus maze
To assess anxiety-like behavior, animals were intro-
duced in the center of an elevated plus maze for 5 min.
The maze was at 40 cm from the ﬂoor with two opposing
protected (closed) arms of 30 cm (length) × 5 cm (wide) ×
15.25 (height), and two opposing unprotected (open) arms
(30 × 5 × 0).Time in the open and closed arms, as well as
the number of entries in each arm were recorded with an
automated video-tracking system (Video Tracking Plus
Maze Mouse; Med Associates, USA).
Dexamethasone suppression test
To test the sensitivity of the HPA axis, mice were
injected intraperitoneally with 0.01 mg/kg of dex-
amethasone (Sigma) or saline. One and a half hours later,
animals were introduced in an open ﬁeld for 10 min to
induce a mild corticosterone increase. 2 and 3 h after the
injection, blood samples were collected. Results are shown
as corticosterone levels of the dexamethasone-treated
animals over the control levels of saline-injected mice.
Blood and tissue collection
As previously described21, blood was collected from the
submandibular vein to reduce pain and distress. Serum
was collected and stored at −20 °C. For FKBP5 mRNA
extraction from whole blood, samples were extracted
either with a cardiac puncture or from the submandibular
vein and immediately homogenized in Trizol LS and
frozen until RNA extraction. To obtain the hippocampi
and hypothalami, animals were anesthetized with pento-
barbital (50 mg/kg, i.p.) and perfused transcardially with
saline. Brains were removed, and the areas were dissected
and frozen in dry ice. Samples were stored at −80 °C until
further use.
Cell cultures and in vitro assays
Brain samples were extracted from E16-17 mice as
previously described50. Meninges and blood vessels were
removed. Then, the structures were minced with scissors
and dissociated with a Pasteur pipette in DMEM-F12.
After brief centrifugation at 1000 rpm, the pellet was
resuspended in Neurobasal medium supplemented with
B27 (Gibco; 395) and Glutamine (Sigma; G3126). Subse-
quently, neuronal and glia cell cultures were seeded onto
six-well plates coated with poly-L-lysine and previously
incubated with 10% of FBS in PBS. Plated cells were kept
in B27 and glutamine-supplemented Neurobasal, in an
atmosphere of 95% O2 and 5% CO2 at 37 °C. One week
after the culture, cells were washed with PBS and fasted
for 3 h with B27-free Neurobasal.
IGF-I administration
In vivo
Alzet osmotic mini-pums (Model 1004; USA) were used
for chronic administration of hIGF-I (Pre-Protech, USA;
50 µg/kg/day) or the vehicle (saline). Pumps were
implanted subcutaneously between the scapulae following
the manufacturer’s instructions. The treatment lasted
25 days. Intracerebroventricular infusion of hIGF-I (1 µg/
day) was carried out with Alzet osmotic mini-pumps
(Model 1002) implanted subcutaneously and attached to a
catheter tube and an infusion cannula (Brain infusion kit
3, Alzet) that was positioned with the stereotaxic frame
into the left lateral ventricle (−0.6 mm from bregma,
1.4 mm lateral and at 2 mm of depth) according to the
manufacturer’s instructions. The treatment lasted 10 days
(see Suppl Figure G for time-line of this experiment).
In vitro
Following the starving period, cells were treated with
rhIGF-I (1 nM) for 24 h. Cells were then tripsinized and
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frozen at −80 °C until RNA extraction. All experiments
were done in triplicate dishes.
ELISA
IGF-I
IGF-I in serum and tissue was determined using a
mouse-speciﬁc ELISA (R&D Systems, USA) as descri-
bed27, following the manufacturer’s instructions.
Corticosterone
Corticosterone in serum was determined using a
species-independent enzyme immunoassay kit (DetectX,
Arbor Assays) following the manufacturer’s instructions.
RNA extraction, reverse transcription and Duplex real-time
qPCR
Total RNA isolation was carried out following the
manufacturer’s instructions with either Trizol (Life
Technologies, USA) for the brain tissue, Trizol LS (Life
Technologies, USA) for whole blood samples or with the
RNA Cell Culture Kit with the MiniQG-80 apparatus for
cell samples. RNA retro-transcription and cDNA ampli-
ﬁcation were performed as previously described21 with a
FKBP5 TaqMan probe (FAM reporter,
Mm00487406_m1), and 18S as endogenous control (VIC
reporter, Life Technologies). A modiﬁed 2(−ΔΔCT)
method51 was used to determine the relative mRNA
quantity.
Human data from the NESDA study
To investigate whether IGF-I was associated with stress
vulnerability measures and FKBP5 in a human sample, we
used data of the Netherlands Study on Depression and
Anxiety (NESDA). NESDA is an ongoing longitudinal
cohort study on predictors, course and consequences of
depressive and anxiety disorders that has been described
in detail elsewhere52. In brief, the NESDA sample consists
of 2981 participants aged 18–65 years, comprising per-
sons with and without depressive and/or anxiety dis-
orders. Exclusion criteria were (1) a primary clinical
diagnosis of a psychiatric disorder not under study in
NESDA (psychotic disorder, obsessive compulsive dis-
order, bipolar disorder, or severe addiction disorder), and
(2) not being ﬂuent in Dutch. Between September 2004
and February 2007, all participants completed the 4-h
baseline assessment at one of the research centers, which
included face-to-face interviews, written questionnaires,
and biological measurements. The research protocol was
approved by the Ethical Committee of the participating
centers. All participants provided written informed con-
sent. We excluded persons for whom no blood was
sampled in NESDA (n= 113), persons whose IGF-I levels
could not be determined by the lab (n= 145), individuals
on growth hormone medication (ATC code H01AC; n=
3), antidepressant medication users with no lifetime
depressive/anxiety disorder (n= 6), and persons with no
glucose measure (n= 28), which resulted in 2686 parti-
cipants to be included in the analysis.
Measurements in NESDA
IGF-I
Fasting EDTA plasma samples were collected in the
morning during the baseline measurement, and kept
frozen at −80 °C until assaying. As described earlier17,
IGF-I (nmol/l) was assayed centrally by chemilumines-
cence immunoassay on the Liaison autoanalyzer (Dia-
Sorin, S.p.A., Italy), with intra-assay and interassay
coefﬁcient of variation of 8.3 and 11.1%, respectively. IGF-
I was studied as a continuous measure. However, as both
low and high IGF-I levels might be associated with poor
health outcomes, sex- and age-speciﬁc quintiles of IGF-I
were also computed.
Negative life events and childhood trauma in NESDA
The number of negative life events in the last year were
measured with the Brugha’s List of Threatening Experi-
ences53 and was expressed as number of negative life
events in the last year. Childhood trauma was measured
with the Childhood Trauma Interview, which measures
the presence of emotional neglect, psychological abuse,
physical abuse, and sexual abuse before age 1654, and was
dichotomized into having a traumatic event in childhood
vs. having no traumatic event in childhood.
Dexamethasone suppression
In a subsample of NESDA participants, saliva was col-
lected to measure dexamethasone suppression. The sali-
vary cortisol measurements have been described before55.
Brieﬂy, respondents were asked to collect saliva samples
at home on a regular (preferably working) day by Saliv-
ettes (Sarstedt AG and Co, Nurmbrecht, Germany) at
seven time points: upon awakening (T1), 30 min (T2),
45 min (T3), and 60 min (T4) after awakening and in the
evening at 2200 hours (T5) and 2300 hours (T6). Imme-
diately after saliva sampling at T6, the cortisol suppres-
sion test was carried out by oral administration of a 0.5-
mg dexamethasone pill and assessed by cortisol sampling
the next morning directly after awakening (T7). Instruc-
tions for the saliva sampling prohibited eating, smoking,
drinking, or brushing teeth within 15min before sampling
and dental work 24 h before sampling. All samples were
refrigerated and returned by mail. During laboratory
analysis, Salivettes were centrifuged at 2000 × g for
10 min, aliquoted, and stored at −80 °C. Competitive
electrochemiluminescence immunoassay (E170, Roche,
Basel, Switzerland) was used to measure cortisol levels56.
The detection limit was 2.0 nmol/l and intra-assay and
interassay variability coefﬁcients in the measuring range
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were <10%. Dexamethasone suppression ratio was calcu-
lated by dividing the cortisol levels at awakening on day 1
(T1) by the post-dexamethasone cortisol value at awa-
kening on day 2 (T7).
FKBP5 gene expression
To assess FKBP5 gene expression in NESDA, venous
whole blood samples were obtained in the morning after
overnight fasting. Heparinized whole blood samples were
transferred within 20min of sampling into PAXgene
Blood RNA tubes (Qiagen, Valencia, California, USA) and
stored at −20 °C before RNA isolation. Gene expression
assays were conducted at the Rutgers University Cell and
DNA Repository (RUCDR, http://www.rucdr.org). Sam-
ples were hybridized to Affymetrix U219 array plates
(GeneTitan), which contains 530,467 probes summarized
in 49,293 probe sets. Array hybridization, washing,
staining, and scanning were carried out in an Affymetrix
GeneTitan System per the manufacturer’s protocol. Gene
expression data were required to pass standard Affymetrix
QC metrics (Affymetrix expression console) before fur-
ther analysis. We removed probes for further analysis that
did not map uniquely to the hg19 (Genome Reference
Consortium Human Build 37) reference genome
sequence, as well as probes targeting a messenger RNA
(mRNA) molecule resulting from a transcription of a
DNA sequence containing a single nucleotide poly-
morphism (based on the dbSNP137 common database),
resulting in 423,201 probes, which could be summarized
into 44,241 probe sets targeting 18,238 genes. Normalized
probe set expression values were obtained using Robust
Multi-array Average (RMA) normalization as imple-
mented in the Affymetrix Power Tools software (APT,
version 1.12.0, Affymetrix).
Further details on RNA processing procedures have
been described before57,58. We calculated the mean
FKBP5 expression across all six probe sets targeting
FKBP5 after adjusting for RNA per plate, position on
plate, month and time of blood withdrawal, level of blood
hemoglobin, and time between blood withdrawal and
RNA extraction.
Covariates in NESDA
Gender, age, education level, and smoking status
(never, past, current) were measured. Weight and height
were measured by trained staff to calculate BMI (kg/m2).
Physical activity was assessed with the International
Physical Activity Questionnaire (IPAQ), and expressed
in 1000 metabolic equivalent (MET) minutes per
week59. Glucose levels were determined using routine
standardized laboratorial methods after an overnight
fast.
Statistical analysis
SPSS Statistics 22 (IBM) and GraphPad Prism 6 soft-
ware (USA) were used to perform statistical analysis.
Depending on the number of independent variables and
the experimental groups compared, either Student’s t test
or Mann−Whitney U test (two groups parametric or
nonparametric) and one-way or two-way ANOVAs (for
more than two groups) followed by Bonferroni’s multiple
comparison test as a post-hoc test were performed.
Results are shown as mean ± standard error (SEM) and p
values coded as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
Linear regression analyses were carried out for the study
of the association between IGF-I and anxiety in mice.
Sample size for each experiment was chosen based on
previous experience and aimed to detect at least a p < 0.05
in the different tests applied. All animals were included in
the statistical analysis, without any exclusion criteria.
Animals were included in each experimental group ran-
domly by the researcher, without blinding.
In NESDA, different types of regression analyses were
performed to study the associations between IGF-I
(independent variable), and each of the stress vulner-
ability measures and FKBP5 (dependent variables). A
Poisson regression model (which provides a rate ratio)
was used for the number of life events; a logistic regres-
sion model was used for childhood trauma (y/n), and
linear regression models were used for dexamethasone
suppression ratio and FKBP5 expression. Due to the
skewed distribution, dexamethasone suppression ratio
was log-transformed before being entered into the
regression model. All analyses were ﬁrst done with IGF-I
as continuous variable (model 1) and were then repeated
with the sex- and age-speciﬁc IGF-I quintiles as inde-
pendent variable (with Q3 as reference category, model 2).
All models were adjusted for gender, age, education level,
smoking, body mass index, physical activity and glucose.
Analyses were done in IBM SPSS version 24, and a p <
0.05 was considered statistically signiﬁcant.
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